Appili Therapeutics (OTCMKTS:APLIF – Get Rating) and Sigilon Therapeutics (NASDAQ:SGTX – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk. Risk & Volatility Appili Therapeutics has a beta of […]
Sigilon Therapeutics (NASDAQ:SGTX – Get Rating) and Appili Therapeutics (OTCMKTS:APLIF – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations. Valuation & Earnings This table compares Sigilon Therapeutics and […]
Frequency Therapeutics (NASDAQ:FREQ – Get Rating) and Appili Therapeutics (OTCMKTS:APLIF – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership. Analyst Recommendations This is a breakdown of recent recommendations […]
PDS Biotechnology (NASDAQ:PDSB – Get Rating) and Appili Therapeutics (OTCMKTS:APLIF – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk. Insider and Institutional Ownership 23.9% of PDS Biotechnology shares […]
Appili Therapeutics reports it has enrolled the last patient for its Phase III study of Avigan/Reeqonus (favipiravir), developed in alliance with AiPharma.